Generate Biomedicines, Inc. (GENB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Generate Biomedicines, Inc. (GENB) trades at $13.35 with AI Score 72/100 (Grade A). Generate Biomedicines, Inc. is a biopharmaceutical company utilizing machine learning to discover and develop novel protein therapeutics. Market cap: $1.71B, Sector: Financial services.
Last analyzed: Mar 16, 2026Analyst Coverage for GENB: GENB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GENB against Financial Services peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
GENB: 1/1 perspectives are bullish.
Generate Biomedicines, Inc. (GENB) Financial Services Profile
Generate Biomedicines, Inc. pioneers generative biology, employing machine learning to design and develop protein-based therapeutics. Their Generate Platform targets a wide range of diseases, positioning them within the innovative drug discovery sector. The company's focus on novel protein modalities distinguishes it from traditional pharmaceutical approaches.
What Is the Investment Thesis for GENB?
Generate Biomedicines presents a unique investment opportunity within the biopharmaceutical sector, driven by its innovative Generate Platform and pipeline of novel protein therapeutics. The company's focus on machine learning-driven drug discovery offers the potential for faster development cycles and more targeted therapies. Key value drivers include the successful clinical development of GB-0895 for severe asthma and the expansion of the Generate Platform to address additional therapeutic areas. However, the company's negative profit margin of -637.0% and reliance on future clinical trial outcomes pose significant risks. The company's market capitalization is $1.55B as of 2026-03-16. Successful execution of clinical trials and strategic partnerships will be crucial for realizing the company's long-term potential.
Based on FMP financials and quantitative analysis
GENB Key Highlights
- Market capitalization of $1.55 billion reflects investor confidence in the company's innovative approach to drug discovery.
- Gross margin of 100.0% indicates strong potential profitability upon successful commercialization of drug candidates.
- Negative profit margin of -637.0% highlights the company's current focus on research and development, with significant investments in its Generate Platform and clinical trials.
- The company's pipeline includes GB-0895, a potential blockbuster drug for severe asthma, targeting a large and underserved patient population.
- The Generate Platform's therapeutic area and protein modality agnostic design offers broad applicability and scalability, potentially leading to multiple drug candidates across various disease areas.
Who Are GENB's Competitors?
GENB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NXDT NexPoint Diversified Real Estate Trust | $5.34 | +0.00% | $276.20M | 73 |
| SII Sprott Inc. | $131.01 | +3.20% | $3.38B | 71 |
| TPZ Tortoise Electrification Infrastructure ETF | $21.67 | +0.00% | $127.64M | 70 |
| IDDTF AB Industrivärden (publ) | $34.25 | +0.00% | $14.79B | 70 |
| IDKFF ThreeD Capital Inc. | $0.08 | +0.00% | $5.72M | 70 |
| WHF WhiteHorse Finance, Inc. | $6.58 | -1.50% | $142.20M | 69 |
| TONX TON Strategy Co. | $3.15 | -2.48% | 179M | 68 |
| AOD Abrdn Total Dynamic Dividend Fund | $10.45 | +0.00% | $1.10B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GENB's Key Strengths?
- Innovative Generate Platform for protein therapeutic design.
- Strong pipeline of drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug discovery and development.
- Potential for rapid drug development cycles due to machine learning approach.
What Are GENB's Weaknesses?
- High research and development costs.
- Reliance on successful clinical trial outcomes.
- Negative profit margin and limited revenue generation.
- Competition from established pharmaceutical companies and other AI-driven drug discovery platforms.
What Could Drive GENB Stock Higher?
- Clinical trial results for GB-0895 in severe asthma (2027).
- Expansion of the Generate Platform into new therapeutic areas.
- Strategic partnerships with pharmaceutical companies.
- Regulatory approval of GB-0895 (2028).
What Are the Key Risks for GENB?
- Failure of clinical trials for GB-0895 or other drug candidates.
- Regulatory delays or rejection of drug approval applications.
- Competition from established pharmaceutical companies and other AI-driven drug discovery platforms.
- Changes in healthcare reimbursement policies that could limit access to the company's drugs.
- High research and development costs that could strain the company's financial resources.
What Are the Growth Opportunities for GENB?
- Expansion of the Generate Platform: The Generate Platform's agnostic design allows for expansion into new therapeutic areas and protein modalities. This offers significant growth potential, as the company can leverage its existing technology to develop treatments for a wide range of diseases. The market for novel protein therapeutics is expected to grow significantly over the next decade, driven by the increasing prevalence of chronic diseases and the demand for more effective and personalized treatments. Timeline: Ongoing.
- Clinical Development of GB-0895: GB-0895, the company's investigational long-acting anti-TSLP monoclonal antibody for severe asthma, represents a significant growth opportunity. If successful in clinical trials, GB-0895 could capture a significant share of the asthma market, which is projected to reach $26 billion by 2029. The drug's potential for six-month dosing could provide a competitive advantage over existing treatments. Timeline: 2026-2028.
- Strategic Partnerships: Generate Biomedicines can accelerate its growth by forming strategic partnerships with established pharmaceutical companies. These partnerships can provide access to funding, expertise, and distribution networks, enabling the company to bring its drug candidates to market more quickly and efficiently. The market for pharmaceutical collaborations is highly active, with numerous deals being announced each year. Timeline: Ongoing.
- Development of GB-4362 and GB-5267: The company's other drug candidates, GB-4362 (an MMAE payload neutralizer monoclonal antibody) and GB-5267 (a MUC16 CAR-T Cell therapy), represent additional growth opportunities. These therapies target specific cancers and have the potential to address unmet medical needs. The market for cancer therapies is expected to continue to grow rapidly, driven by the aging population and advances in cancer research. Timeline: 2027-2030.
- Geographic Expansion: While currently focused on the United States, Generate Biomedicines can expand its operations to other geographic regions, such as Europe and Asia. These regions offer significant market opportunities, particularly for innovative therapies that address unmet medical needs. Expanding internationally would require significant investment and regulatory approvals, but could significantly increase the company's revenue and profitability. Timeline: 2028-2030.
What Opportunities Does GENB Have?
- Expansion of the Generate Platform into new therapeutic areas.
- Strategic partnerships with pharmaceutical companies.
- Successful commercialization of GB-0895 for severe asthma.
- Development of personalized therapies based on individual patient data.
What Threats Does GENB Face?
- Regulatory hurdles and delays in drug approval.
- Failure of clinical trials.
- Competition from biosimilars and generic drugs.
- Changes in healthcare reimbursement policies.
What Are GENB's Competitive Advantages?
- Proprietary Generate Platform: The company's machine learning-driven platform for designing novel protein therapeutics provides a significant competitive advantage.
- Strong Intellectual Property: Patents on its drug candidates and platform technology protect the company's innovations from competitors.
- Expert Team: The company's team of scientists and engineers has expertise in machine learning, protein engineering, and drug development.
- First-Mover Advantage: As an early entrant in the field of generative biology, the company has a head start in developing and commercializing this technology.
What Does GENB Do?
Founded in 2018 and based in Somerville, Massachusetts, Generate Biomedicines, Inc. is at the forefront of generative biology, leveraging machine learning to revolutionize drug discovery and development. The company's core technology, the Generate Platform, is designed to program novel protein therapeutics, addressing therapeutic challenges that are beyond the scope of conventional methods. This platform integrates computational innovation with scalable biohardware, enabling the creation of a diverse range of protein-based modalities for drug development. Generate Biomedicines' pipeline includes several promising drug candidates. GB-0895, an investigational long-acting anti-TSLP monoclonal antibody, is being developed for severe asthma with a target dosing frequency of every six months. Other notable products include GB-4362, an MMAE payload neutralizer monoclonal antibody, and GB-5267, a MUC16 CAR-T Cell therapy. The company was formerly known as Generate Biologics, Inc., changing its name in February 2020 to reflect its expanded focus on biomedicines. Generate Biomedicines is committed to transforming the therapeutic landscape by harnessing the power of machine learning to design and develop innovative protein therapeutics.
What Products and Services Does GENB Offer?
- Develops novel protein therapeutics using machine learning.
- Utilizes the Generate Platform, a technology integrating computational innovation with scalable biohardware.
- Creates protein-based modalities for drug development.
- Focuses on therapeutic areas beyond the reach of traditional technologies.
- Designs therapies for diseases with unmet medical needs.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks strategic partnerships to accelerate drug development and commercialization.
How Does GENB Make Money?
- Develops and patents novel protein therapeutics.
- Out-licenses or co-develops drug candidates with pharmaceutical partners.
- Generates revenue through milestone payments and royalties on partnered drugs.
- Potentially manufactures and sells its own drugs upon regulatory approval.
What Industry Does GENB Operate In?
Generate Biomedicines operates within the rapidly evolving biopharmaceutical industry, where machine learning and artificial intelligence are increasingly being used to accelerate drug discovery and development. The market for AI-driven drug discovery is projected to reach $4 billion by 2028, driven by the need for faster, more efficient, and more targeted therapies. Generate Biomedicines competes with both traditional pharmaceutical companies and other AI-driven drug discovery platforms. The company's unique approach to programming novel protein therapeutics positions it as a potential leader in this emerging field.
Who Are GENB's Key Customers?
- Pharmaceutical companies seeking innovative drug candidates.
- Patients with diseases that are not adequately treated by existing therapies.
- Healthcare providers who prescribe the company's drugs.
- Research institutions interested in collaborating on drug discovery and development.
GENB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Generate Biomedicines has recently seen positive insider activity, indicating confidence from leadership in the company's future prospects.
- Social sentiment has shifted favorably, with increasing discussions around their innovative approach to protein therapeutics capturing investor interest.
- Recent partnerships and collaborations in the biopharmaceutical space have boosted market perception of GENB's potential for groundbreaking developments.
- The growing emphasis on personalized medicine aligns well with GENB's focus, positioning them favorably in a rapidly evolving healthcare landscape.
Bear Case
- Despite recent positive sentiment, some investors remain cautious due to the inherent risks associated with biotech development timelines.
- Community discussions have highlighted concerns over regulatory hurdles that could delay product approvals and commercialization.
- Market perception is tempered by the competitive landscape, with many players vying for similar advancements in the biotech sector.
- Recent volatility in broader biotech stocks has led to skepticism about GENB's ability to maintain momentum amid market uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7M | -$61M | $-0.48 |
Based on FMP financials and quantitative analysis
GENB Latest News
-
NVIDIA Corporation Increases Stake In CoreWeave To 47,213,353 Shares, Maintains Holdings In Intel Corporation (214,776,632 Shares), Nebius Group N.V. (1,190,476 Shares), Nokia Corporation (166,389,351 Shares), Synopsys (4,821,717 Shares), Takes New Stakes In Coherent Corp. (7,788,161 Shares) Generate Biomedicines (833,325 Shares).
benzinga · May 15, 2026
-
Nvidia Takes New Stake In Generate Biomedicines With 833,325 Shares
benzinga · May 15, 2026
-
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga · Apr 13, 2026
GENB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GENB.
Price Targets
Wall Street price target analysis for GENB.
GENB MoonshotScore
What does this score mean?
The MoonshotScore rates GENB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
NVIDIA Corporation Increases Stake In CoreWeave To 47,213,353 Shares, Maintains Holdings In Intel Corporation (214,776,632 Shares), Nebius Group N.V. (1,190,476 Shares), Nokia Corporation (166,389,351 Shares), Synopsys (4,821,717 Shares), Takes New Stakes In Coherent Corp. (7,788,161 Shares) Generate Biomedicines (833,325 Shares).
Nvidia Takes New Stake In Generate Biomedicines With 833,325 Shares
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Leadership: Mike Nally
CEO
Mike Nally serves as the CEO of Generate Biomedicines, bringing extensive experience in the biopharmaceutical industry. Prior to joining Generate, Nally held leadership positions at leading pharmaceutical companies, including Merck and Biogen. His background includes a strong track record in commercial strategy, product development, and global marketing. Nally's expertise spans various therapeutic areas, including immunology, oncology, and neurology. He holds advanced degrees in business and science, providing a comprehensive understanding of the biopharmaceutical landscape.
Track Record: Since joining Generate Biomedicines, Mike Nally has focused on advancing the company's Generate Platform and pipeline of novel protein therapeutics. He has overseen the initiation of clinical trials for GB-0895 and has forged strategic partnerships to accelerate drug development. Under his leadership, Generate Biomedicines has strengthened its position as a leader in generative biology and AI-driven drug discovery.
Common Questions About GENB (Financial Services)
What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc. is a biopharmaceutical company pioneering the field of generative biology. They utilize machine learning to design and develop novel protein therapeutics, addressing diseases that are difficult to treat with traditional methods. Their core technology, the Generate Platform, integrates computational innovation with scalable biohardware, enabling the creation of a diverse range of protein-based modalities. The company's pipeline includes drug candidates for severe asthma, cancer, and other diseases, positioning them as an innovator in the pharmaceutical industry.
What do analysts say about GENB stock?
AI analysis is pending for Generate Biomedicines, Inc. (GENB). Once available, the AI analysis will provide a neutral summary of analyst consensus, key valuation metrics, and growth considerations. As of 2026-03-16, the company's market capitalization is $1.55 billion, with a P/E ratio of -3.01 and a negative profit margin of -637.0%. These metrics reflect the company's current focus on research and development, with significant investments in its Generate Platform and clinical trials. Investors should carefully consider these factors when evaluating the company's potential.
What are the main risks for GENB?
Generate Biomedicines, Inc. faces several key risks, including the potential failure of clinical trials for its drug candidates, regulatory delays or rejection of drug approval applications, and competition from established pharmaceutical companies and other AI-driven drug discovery platforms. The company's high research and development costs and negative profit margin also pose financial risks. Additionally, changes in healthcare reimbursement policies could limit access to the company's drugs, impacting revenue and profitability. Investors should carefully assess these risks before investing in GENB.
What are the key factors to evaluate for GENB?
Generate Biomedicines, Inc. (GENB) holds an AI score of 72/100 (high). Not financial advice.
How frequently does GENB data refresh on this page?
GENB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GENB's recent stock price performance?
Generate Biomedicines, Inc. (GENB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Generate Platform for protein therapeutic design. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GENB overvalued or undervalued right now?
Valuing Generate Biomedicines, Inc. (GENB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GENB?
Before investing in Generate Biomedicines, Inc. (GENB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide additional insights.
- Financial data is based on available information and may be subject to change.
- Clinical trial outcomes are uncertain and could impact the company's future prospects.